https://www.selleckchem.com/pr....oducts/cevidoplenib-
Pazopanib, a multitargeted tyrosine kinase inhibitor, is recommended as the standard treatment for refractory soft tissue sarcoma (STS). However, there are comparatively few molecular determinants for predicting pazopanib efficacy. Based on correlative studies regarding the predictive impact of PD-L1, we investigated the clinical relevance of PD-L1 expression and evaluated its value for predicting pazopanib efficacy. Tumour tissues from patients with advanced STS who went on to receive pazopanib were assessed for PD-L1 e
Like
Comment
Share
